Medicine & Life Sciences
Acute Myeloid Leukemia
100%
Mutation
71%
Leukemia
70%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
64%
Protein-Tyrosine Kinases
56%
Dasatinib
51%
Imatinib Mesylate
50%
Neoplasms
48%
B-Cell Chronic Lymphocytic Leukemia
47%
Precursor Cell Lymphoblastic Leukemia-Lymphoma
43%
Phosphotransferases
42%
Philadelphia Chromosome
33%
Bone Marrow
32%
Leukemia, Neutrophilic, Chronic
29%
Cytogenetics
29%
ponatinib
28%
Colony-Stimulating Factor Receptors
27%
B-Lymphocytes
27%
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
27%
idelalisib
27%
Phosphorylation
26%
Therapeutics
25%
Myeloid Cells
24%
Tyrosine
23%
Stents
23%
Alleles
23%
Syk Kinase
22%
Leukemia, Myeloid, Chronic Phase
21%
Myeloproliferative Disorders
21%
In Vitro Techniques
19%
Transjugular Intrahepatic Portasystemic Shunt
19%
6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine
18%
Leukemia, Myelomonocytic, Chronic
18%
Proteins
18%
4-(3-(2H-1,2,3-triazol-2-yl)phenylamino)-2-(2-aminocyclohexylamino)pyrimidine-5-carboxamide
17%
CPI203
17%
Swine
17%
Chromosome Aberrations
16%
Transplants
16%
Cell Line
16%
Signal Transduction
16%
5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine
15%
Janus Kinase Inhibitors
15%
CRKL protein
15%
N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide
15%
CPX-351
15%
Pharmaceutical Preparations
15%
RNA Interference
14%
Cyclic AMP-Dependent Protein Kinases
14%
Animals
14%